Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy Designation
Abstract In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability. The development of regenerative medicines is very challenging because of their complex and unique nature, especially to the rather unexperienced small- and medium-sized developing enterprises. With the new RMAT designation, FDA aims at providing intensive support to companies developing cell- and tissue-based therapies, tissue-engineering products, and combination treatments. This may also include cell-based products where the genome has been edited by emerging technologies such as CRISPR-Cas9. This article presents the newly launched “Regenerative Medicine Advanced Therapy” (RMAT) designation, outlines existing FDA regulatory tools aiming at expediting approval, and discusses the overall value of these programs. Additionally, recommendations are provided for companies developing these very specific and complex therapies on how and when to consider these tools for an integrated development and regulatory strategy..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
---|---|
Enthalten in: |
Therapeutic innovation & regulatory science - 53(2019), 3 vom: Mai, Seite 364-373 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Vaggelas, Annegret [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
CAR T cell |
---|
Anmerkungen: |
© Drug Information Association, Inc 2018 |
---|
doi: |
10.1177/2168479018779373 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR038929856 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR038929856 | ||
003 | DE-627 | ||
005 | 20230519124327.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1177/2168479018779373 |2 doi | |
035 | |a (DE-627)SPR038929856 | ||
035 | |a (SPR)2168479018779373-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Vaggelas, Annegret |e verfasserin |0 (orcid)0000-0003-3578-0054 |4 aut | |
245 | 1 | 0 | |a Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy Designation |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Drug Information Association, Inc 2018 | ||
520 | |a Abstract In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability. The development of regenerative medicines is very challenging because of their complex and unique nature, especially to the rather unexperienced small- and medium-sized developing enterprises. With the new RMAT designation, FDA aims at providing intensive support to companies developing cell- and tissue-based therapies, tissue-engineering products, and combination treatments. This may also include cell-based products where the genome has been edited by emerging technologies such as CRISPR-Cas9. This article presents the newly launched “Regenerative Medicine Advanced Therapy” (RMAT) designation, outlines existing FDA regulatory tools aiming at expediting approval, and discusses the overall value of these programs. Additionally, recommendations are provided for companies developing these very specific and complex therapies on how and when to consider these tools for an integrated development and regulatory strategy. | ||
650 | 4 | |a RMAT |7 (dpeaa)DE-He213 | |
650 | 4 | |a cell therapies |7 (dpeaa)DE-He213 | |
650 | 4 | |a gene therapies |7 (dpeaa)DE-He213 | |
650 | 4 | |a expedited programs |7 (dpeaa)DE-He213 | |
650 | 4 | |a CAR T cell |7 (dpeaa)DE-He213 | |
650 | 4 | |a genome editing |7 (dpeaa)DE-He213 | |
700 | 1 | |a Seimetz, Diane |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Therapeutic innovation & regulatory science |d [New York] : Springer Nature, 2013 |g 53(2019), 3 vom: Mai, Seite 364-373 |w (DE-627)SPR038904640 |w (DE-600)2708397-4 |x 2168-4804 |7 nnns |
773 | 1 | 8 | |g volume:53 |g year:2019 |g number:3 |g month:05 |g pages:364-373 |
856 | 4 | 0 | |u https://dx.doi.org/10.1177/2168479018779373 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 53 |j 2019 |e 3 |c 05 |h 364-373 |